Pembrolizumab Shows Improvements in Disease-Free Survival as Adjuvant Treatment for Non-Small Cell Lung Cancer
The findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer.New study results...
